World Orphan Drug Congress Europe's highly anticipated pre-congress workshops are back!
Designed for in-depth discussions and insights into orphan drug and rare disease progress, our workshops on 22 October, 2024, will cover everything from AI to the Rare Disease Action Plan.
Reserve your seat today with our discounted ticket package ,which grants you full access to the Workshops (22 October, 2024) and Conference Sessions & Exhibition (23-25 October, 2024)
- The Micro level of the individual, i.e., the patient (also including individual physicians and patient representatives)
- The Meso level of healthcare resources, such as healthcare institutions and healthcare systems
- BThe Macro level of healthcare provision, including payers, insurers, regulators, taking into account impact outside the healthcare systems and its stakeholders, e.g. on society, for employers, non-paid work, etc.
- Christopher M de M Rudolf, Founder & CEO, Volv Global
- Leon van Wouwe, Clinical Innovation Director, Volv Global
Sponsored by Clinigen
Key Topics:
- Unique challenges in rare disease drug development and the need for a comprehensive approach
- ESG in Rare Disease: discuss how environmental, social and governance factors are becoming increasingly important in the rare disease space
- Emphasise the social impact of developing treatments for underserved populations
- Kieron Lewis, Director of Strategic Consulting, Clinigen
- Nicholas Brooke, Founder, The Synergist & Executive Director, PFMD
- Lorna Pender, Patient Group Lead, Clinigen
Sponsored by Chiesi
Key topics:
- What are the gaps in the diagnosis journey of patients across member states and which patient-centric solutions can be sped up in the process?
- How can we reframe the conversation on rare diseases with a health equity lens, placing the patients and caregivers firmly at the centre of all discussions?
- How can we demonstrate that the availability of treatments creates positive societal value?
- What is needed at the EU level to improve equity of access to diagnostics and treatments?
Workshop Speakers:
- Neil Bertelsen, Patient Engagement Specialist and Board Member, PFMD & Steering Committee Member, HTAi
- Peter Fish, CEO, Mendelian
Sponsored by Sanofi
Session Objectives:
- To identify the interconnections needed
- To ensure efficiency of the system
- To avoid fragmentation of strategy and actions
- To identify the appropriate use of the resources
Workshop speakers:
- Anne-Sophie Chalandon, Head of Rare Diseases Global Public Affairs Rare Disease and ATMP Policy, Sanofi & leading IFPMA Rare Diseases Group
- Valentina Botarelli, Public Affairs, Director, Head of European Advocacy, EURORDIS
- Alexandra Heumber Perry, CEO, Rare Diseases International
- Dr Virginie Bros-Facer, CEO, EURORDIS - Rare Disease Group
- Ulrike Schwerdtfeger, Legal Technical Officer, WHO
Sponsored by Partners4Access
Workshop Leader:
- Sophie Schmitz, Managing Partner, Partners4Access & leading IFPMA Rare Diseases Group
- Darren Callanan, Global Digital Lead, Partners4Access
- Oriol Solà-Morales, Chair & Founder, HiTT
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events